Aurore to merge with Solara in an all-stock transaction
The merger is in line with Solara’s strategy of accelerating growth via appropriate inorganic actions
The merger is in line with Solara’s strategy of accelerating growth via appropriate inorganic actions
Production of Sputnik V at Panacea Biotec sites will help facilitate global supply of Sputnik V to international partners of RDIF
The promoter holding in the company has increased to 37.25%, a rise of 4.9% from 32.35% as of 31 March 2020
India produces 60% of the world’s vaccine
NPPA also fixed retail price of 76 new drugs in the meeting dated 10th March 2021 to be launched by existing manufacturers including off-patent Anti-diabetic drugs allowing due benefit of patent expiry to the patients.
Has signed a 12-year, off-site, virtual power purchase agreement (VPPA) with Enel Green Power
The vaccine was 85 percent effective in preventing severe disease across all regions.
AdCOVID is a COVID-19 vaccine candidate that is administered via nasal spray.
The next phase of growth in pharma depends on the industry-oriented workforce, risk investment, academic revamp, and creation of R&D hubs, say experts .
The Indian pharma industry has grown at a compounded growth rate of ~11% in the domestic market and ~16% in exports over the last two decades
Subscribe To Our Newsletter & Stay Updated